Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mikkel Højlund & Christoph U. Correll. (2023) Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches. Expert Opinion on Pharmacotherapy 24:13, pages 1463-1489.
Read now
Read now
David Taylor, Ramalingam Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Hansen, Gavin P. Reynolds & Sofia Pappa. (2023) Dopamine partial agonists: a discrete class of antipsychotics. International Journal of Psychiatry in Clinical Practice 27:3, pages 272-284.
Read now
Read now
Rui-Xiang Yuan, Jun-Wei Xu, Lian-Hua Song, Yang-Li Qi, Hong Mou, Jian-Wei Wu, Ke-Yu Jiang & Xiao-Wen Chen. (2021) A convenient and practical synthesis of the cis isomer of the first orally active dopamine D3-Preferring D3-D2 receptor partial agonist cariprazine. Synthetic Communications 51:14, pages 2127-2134.
Read now
Read now
Federico Mucci, Alessandra Della Vecchia, Stefano Baroni & Donatella Marazziti. (2021) Cariprazine as a therapeutic option for schizophrenia: a drug evaluation. Expert Opinion on Pharmacotherapy 22:4, pages 415-426.
Read now
Read now
Giancarlo Cerveri, Camilla Gesi & Claudio Mencacci. (2019) Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatric Disease and Treatment 15, pages 1525-1535.
Read now
Read now
Articles from other publishers (26)
Luyao Cai, Guanjie Chen, Haichen Yang & Yuanhan Bai. (2023) Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review. International Clinical Psychopharmacology 38:4, pages 249-260.
Crossref
Crossref
Lena Machetanz, Steffen Lau & Johannes Kirchebner. (2023) Cariprazine in offender patient with acute psychosis and aggressive behavior: Case report. Psychiatry Research Case Reports 2:1, pages 100094.
Crossref
Crossref
John Cookson & Jonathan Pimm. (2021) Partial agonists of dopamine receptors: mechanisms and clinical effects of aripiprazole, brexpiprazole and cariprazine. BJPsych Advances 29:2, pages 145-150.
Crossref
Crossref
Ashish Patel, Arya Patel, Darshini Patel, Krina Patel & Tushar Bambharoliya. (2023) Mini Review on Cariprazine: A Promising Antipsychotic Agent. CNS & Neurological Disorders - Drug Targets 22:2, pages 226-236.
Crossref
Crossref
Cristian-Daniel Llach, Anna Giménez-Palomo & Eduard Vieta. (2022) Uso de cariprazina en el trastorno bipolar: una revisión sistemática y aspectos prácticos. Psiquiatría Biológica 29:3, pages 100378.
Crossref
Crossref
Tommaso Vannucchi, Costanza Taddeucci & Lorenzo Tatini. (2022) Case Report: Functional and Symptomatic Improvement With Cariprazine in Various Psychiatric Patients: A Case Series. Frontiers in Psychiatry 13.
Crossref
Crossref
Miguel Bajouco & David Mota. (2022) Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series. Neuropsychiatric Disease and Treatment Volume 18, pages 1351-1362.
Crossref
Crossref
George T. Kannarkat, Stanley N. Caroff & James F. Morley. (2022) Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents. Tremor and Other Hyperkinetic Movements 12:1.
Crossref
Crossref
Filipa Viegas, Tiago Ferreira & Cláudia Campos. (2022) Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone – Clinical Cases. Neuropsychiatric Disease and Treatment Volume 18, pages 1145-1149.
Crossref
Crossref
Emanuela Dyrmishi, Marco De Pieri, Marco Ferrari, Rafael Traber, Matteo Preve, Luca De Peri & Emilio Bolla. (2022) Case Report: Long-Acting Oral Cariprazine. Frontiers in Psychiatry 13.
Crossref
Crossref
Stanislav V. Ivanov, Anatoly B. Smulevich, Evgeniya I. Voronova, Kausar K. Yakhin, Tangyul Z. Beybalaeva & Alena A. Katok. (2022) Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study). Frontiers in Psychiatry 12.
Crossref
Crossref
Rajdip Barman, Pradipta Majumder, Tejaswini Doifode & Anita Kablinger. (2021) Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?. World Journal of Psychiatry 11:12, pages 1228-1238.
Crossref
Crossref
Ricardo Coentre, Rodrigo Saraiva, Carolina Sereijo & Pedro Levy. (2021) Cariprazine Use in Early Psychosis: Three Case Reports. Frontiers in Psychiatry 12.
Crossref
Crossref
Maris Taube. (2021) Case Report: Severe Side Effects Following Treatment With First Generation Antipsychotics While Cariprazine Leads to Full Recovery. Frontiers in Psychiatry 12.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Nicole Moschny, Gudrun Hefner, Renate Grohmann, Gabriel Eckermann, Hannah B Maier, Johanna Seifert, Johannes Heck, Flverly Francis, Stefan Bleich, Sermin Toto & Catharina Meissner. (2021) Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics. Pharmaceuticals 14:6, pages 514.
Crossref
Crossref
Hiroshi Kimura, Nobuhisa Kanahara & Masaomi Iyo. (2021) Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behavioural Brain Research 403, pages 113126.
Crossref
Crossref
S.V. Ivanov & E.I. Voronova. (2021) The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 121:9, pages 139.
Crossref
Crossref
Meghan Musselman, Justin Faden & Leslie Citrome. (2021) Asenapine: an atypical antipsychotic with atypical formulations. Therapeutic Advances in Psychopharmacology 11, pages 204512532110352.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2021) Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard Review of Psychiatry 29:1, pages 20-34.
Crossref
Crossref
Leandro da Costa Lane Valiengo & Ulrich Palm. 2021. Transcranial Direct Current Stimulation in Neuropsychiatric Disorders. Transcranial Direct Current Stimulation in Neuropsychiatric Disorders
501
510
.
Eraldo F Nicotra, Daniele Lecca, Gianluca Casu, Mario Palomba, Annesha Sil & Giorgio Marchese. (2020) Lights and shadows of schizophrenia therapy research: Lessons from oral risperidone and olanzapine. Journal of Psychopharmacology 34:5, pages 574-579.
Crossref
Crossref
A.B. Smulevich, S.V. Ivanov, K.K. Yakhin, E.I. Voronova, G.S. Kharkova, E.I. Skurygina, M.V. Konohova, T.Z. Beybalaeva & A.A. Katok. (2020) Cariprazine in schizophrenia with predominantly negative symptoms: early effects of therapy (observational study). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:12, pages 67.
Crossref
Crossref
Stephen M. Stahl, Sarah Laredo & Debbi Ann Morrissette. (2020) Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Therapeutic Advances in Psychopharmacology 10, pages 204512532090575.
Crossref
Crossref
Esther S. Lee, Hal Kronsberg & Robert L. Findling. (2020) Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. Child and Adolescent Psychiatric Clinics of North America 29:1, pages 183-210.
Crossref
Crossref
Leslie Citrome. (2019) Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. International Journal of Clinical Practice 73:10.
Crossref
Crossref